Letai A - Search Results

1

Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics.

Sarosiek KA, Fraser C, Muthalagu N, Bhola PD, Chang W, McBrayer SK, Cantlon A, Fisch S, Golomb-Mello G, Ryan JA, Deng J, Jian B, Corbett C, Goldenberg M, Madsen JR, Liao R, Walsh D, Sedivy J, Murphy DJ, Carrasco DR, Robinson S, Moslehi J, Letai A. Sarosiek KA, et al. Among authors: letai a. Cancer Cell. 2017 Jan 9;31(1):142-156. doi: 10.1016/j.ccell.2016.11.011. Epub 2016 Dec 22. Cancer Cell. 2017. PMID: 28017613 Free PMC article.

2

Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics.

Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Letai A, et al. Cancer Cell. 2002 Sep;2(3):183-92. doi: 10.1016/s1535-6108(02)00127-7. Cancer Cell. 2002. PMID: 12242151 Free article.

3

BH3 domains as BCL-2 inhibitors: prototype cancer therapeutics.

Letai A. Letai A. Expert Opin Biol Ther. 2003 Apr;3(2):293-304. doi: 10.1517/14712598.3.2.293. Expert Opin Biol Ther. 2003. PMID: 12662143

4

Antiapoptotic BCL-2 is required for maintenance of a model leukemia.

Letai A, Sorcinelli MD, Beard C, Korsmeyer SJ. Letai A, et al. Cancer Cell. 2004 Sep;6(3):241-9. doi: 10.1016/j.ccr.2004.07.011. Cancer Cell. 2004. PMID: 15380515 Free article.

5

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.

Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, Ovaa H, Berkers C, Nicholson B, Chao TH, Neuteboom ST, Richardson P, Palladino MA, Anderson KC. Chauhan D, et al. Among authors: letai a. Cancer Cell. 2005 Nov;8(5):407-19. doi: 10.1016/j.ccr.2005.10.013. Cancer Cell. 2005. PMID: 16286248 Free article.

6

Growth factor withdrawal and apoptosis: the middle game.

Letai A. Letai A. Mol Cell. 2006 Mar 17;21(6):728-30. doi: 10.1016/j.molcel.2006.03.005. Mol Cell. 2006. PMID: 16543140 Free article. Review.

7

Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members.

Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, Letai A. Certo M, et al. Among authors: letai a. Cancer Cell. 2006 May;9(5):351-65. doi: 10.1016/j.ccr.2006.03.027. Cancer Cell. 2006. PMID: 16697956 Free article.

8

Restoring cancer's death sentence.

Letai A. Letai A. Cancer Cell. 2006 Nov;10(5):343-5. doi: 10.1016/j.ccr.2006.10.014. Cancer Cell. 2006. PMID: 17097553 Free article.

9

BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents.

Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. Deng J, et al. Among authors: letai a. Cancer Cell. 2007 Aug;12(2):171-85. doi: 10.1016/j.ccr.2007.07.001. Cancer Cell. 2007. PMID: 17692808 Free article.

10

Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion.

Deng J, Shimamura T, Perera S, Carlson NE, Cai D, Shapiro GI, Wong KK, Letai A. Deng J, et al. Among authors: letai a. Cancer Res. 2007 Dec 15;67(24):11867-75. doi: 10.1158/0008-5472.CAN-07-1961. Cancer Res. 2007. PMID: 18089817

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

215 results

Search Page

Filters